Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, rifamycins may cause your body to process your diabetes medicine more quickly.
What might happen:
A decrease in the beneficial effects of your diabetes medicine may occur.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want you to check your blood sugar more often and your doctor may need to adjust the dose of your diabetes medicine. If you experience pale skin, blurred vision, loss of consciousness, increased thirst, increased urination, blurred vision, fatigue, or fast, deep breathing, contact your doctor.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Park JY, Kim KA, Park PW, Park CW, Shin JG. Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. Clin Pharmacol Ther 2003 Oct;74(4):334-40.
2.Zheng HX, Huang Y, Frassetto LA, Benet LZ. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther 2009 Jan;85(1):78-85.
3.Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 2001 Jun;69(6):400-6.
4.Surekha V, Peter JV, Jeyaseelan L, Cherian AM. Drug interaction: rifampicin and glibenclamide. Natl Med J India 1997 Jan-Feb;10(1):11-2.
5.Zilly W, Breimer DD, Richter E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol 1975 Dec 19;9(2-3):219-27.
6.Self TH, Morris T. Interaction of rifampin and chlorpropamide. Chest 1980 Jun;77(6):800-1.
7.Kihara Y, Otsuki M. Interaction of gliclazide and rifampicin. Diabetes Care 2000 Aug;23(8):1204-5.
8.Self TH, Tsiu SJ, Fowler JW Jr. Interaction of rifampin and glyburide. Chest 1989 Dec;96(6):1443-4.
9.Niemi M, Kivisto KT, Backman JT, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride. Br J Clin Pharmacol 2000 Dec;50(6):591-5.
10.Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2000 Nov;68(5):495-500.
11.Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006 Jan;61(1):70-8.
12.Actos (pioglitazone hydrochloride) US prescribing information. Takeda Pharmaceuticals Inc. November, 2013.
13.Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004 Sep;76(3):239-49.
14.Park JY, Kim KA, Kang MH, Kim SL, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004 Mar;75(3):157-62.